RxDoctor Payments Data

Jaspaul Bhangoo, MD

Internal Medicine · Denton, TXNPI 1932311958

Payments from drug & device makers

$580in general payments, 2019–2025

Across 26 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$389
  • Esperion Therapeutics, Inc.$87
  • Sumitomo Pharma America, Inc.$59
  • Amgen$17
  • Phathom Pharmaceuticals, Inc.$14
  • GSK$13

What the payments were for

  • Food & beverage$580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$580 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$298,119
Medicare patients
520
Services billed
3,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$113,549
JardianceEmpagliflozin82$72,904
MounjaroTirzepatide48$48,266
FarxigaDapagliflozin Propanediol43$48,082
JanuviaSitagliptin Phosphate24$34,192
GemtesaVibegron39$28,884
MyrbetriqMirabegron40$28,077
VascepaIcosapent Ethyl19$18,359
JanumetSitagliptin Phos/Metformin Hcl15$16,231
Icosapent Ethyl58$15,364
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,180
Levothyroxine Sodium1,262$13,017
Tresiba Flextouch U-100Insulin Degludec16$12,342
EliquisApixaban22$9,545
Rosuvastatin Calcium768$9,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$389$63,26268 claims
Sumitomo Pharma America, Inc.Gemtesa$59$28,88439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →